Myomaker Bio, a Loughborough University spin-out, has launched a world-first lab-grown human muscle platform for drug developers. Boehringer Ingelheim...
Read MoreMSK researchers have reported encouraging long-term follow-up results from a small phase 1 trial of a personalised mRNA vaccine...
Read MoreTransgene has completed patient randomisation in the phase 2 part of its phase 1/2 TG4050 trial in head and...
Read MoreKainova Therapeutics has dosed the first patient in Europe in its DOMISOL phase 1/2 trial of DT 7012, expanding...
Read MoreBiogen has secured US FDA approval for a high dose Spinraza regimen for spinal muscular atrophy. Viridian Therapeutics has...
Read MoreDNA Script is expanding access to its SYNTAX platform across Latin America, South Korea and Japan through new distribution...
Read More